0
Original Research: COPD |

Tiotropium and Simplified Detection of Dynamic Hyperinflation*

Arthur F. Gelb, MD, FCCP; Colleen Flynn Taylor, MA; Patricia A. McClean, MSc; Chris M. Shinar, PharmD; Marcelo T. Rodrigues, MD, PhD; Carlos A. Gutierrez, MD, MSc; Kenneth R. Chapman, MD, MSc, FCCP; Noe Zamel, MD, FCCP
Author and Funding Information

*From the Department of Pharmacy Services (Dr. Shinar), Lakewood Regional Medical Center, Lakewood, CA; and Geffen School of Medicine at UCLA (Dr. Gelb), Los Angeles, CA; and Faculty of Medicine (Drs. Gutierrez, Rodrigues, Chapman, and Zamel, and Ms. McClean), University of Toronto, Toronto, ON. Canada.

Correspondence to: Arthur F. Gelb, MD, FCCP, 3650 E South St, Suite 308, Lakewood, CA 90712; e-mail: afgelb@msn.com



Chest. 2007;131(3):690-695. doi:10.1378/chest.06-1662
Text Size: A A A
Published online

Study objective: To detect dynamic hyperinflation (DH) by evaluating reduction in inspiratory capacity (IC) during metronome-paced hyperventilation (MPH) in patients with moderate-to-severe COPD, studied before and after treatment with tiotropium.

Methods: IC and FEV1 were measured before and immediately after MPH at two times resting the respiratory rate for 20 s in 60 COPD patients (28 men; mean age, 66 ± 10 years [± SD]) before and after 30 days of treatment with tiotropium bromide, 18 μg. Patients were encouraged to maintain a constant tidal volume during MPH.

Results: At baseline, mean FEV1 was 1.5 ± 0.1 L (± SE) [57 ± 1.6% of predicted], mean FVC was 2.6 ± 0.1L (77 ± 1.8% of predicted), and mean FEV1/FVC was 56 ± 1%. After 180 μg of aerosolized albuterol sulfate, mean FEV1 was 1.7 ± 0.1 L (63 ± 1.5% of predicted) [p < 0.001] and mean FEV1/FVC was 58 ± 1%. Compared to baseline, after 30 days and 1.5 h after tiotropium there was an increase in IC of 0.18 ± 0.04L (p < 0.0001); FEV1 of 0.13 ± 0.03 L (5.6 ± 0.8% of predicted; p = 0.0002); FVC of 0.22 ± 0.05 L (6.5 ± 1.3% of predicted; p < 0.001); and decrease in end-expiratory lung volume (EELV)/total lung capacity (TLC) of − 3.1 ± 0.6% (p = 0.0001); a decrease in end-inspiratory lung volume (EILV)/TLC of − 2.9 ± 1.3% (p = 0.03); and no change in TLC (− 0.06 ± 0.05 L). Results following MPH-induced DH at baseline and after 30 days of tiotropium were similar, with decreases in IC (− 0.35 ± 0.03 L; p < 0.001); FEV1 (− 0.05 ± 0.04 L; p = 0.2); and FVC (− 0.22 ± 0.03 L; p < 0.0001); no change in TLC; and increases in EELV/TLC (11.8 ± 1.0% of predicted; p < 0.0001) and EILV/TLC (4.0 ± 1.3% of predicted, p < 0.003).

Conclusion: In patients with moderate-to-severe COPD, tiotropium did not reduce MPH-induced DH and reduction in IC, compared to baseline. However, because tiotropium induced bronchodilation and increased baseline IC, lower operational lung volumes may blunt the effect of MPH-induced DH. The noninvasive simplicity of MPH-induced DH provides a clinically useful screening surrogate to monitor changes in IC following treatment with tiotropium.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543